Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Xie X, He Y, Li H, Yu D, Na L, Sun T, Zhang D, Shi X, Xia Y, Jiang T, Rong S, Yang S, Ma X, Xu G
Journal
Nutrition (Burbank, Los Angeles County, Calif.)
Year
2019
Keywords:
Colorectal cancer, Immune system, Intestinal microbiota, Operation, Prebiotics
OBJECTIVE: The aim of the present study was to investigate the effects of prebiotics (containing fructooligosaccharides, xylooligosaccharides, polydextrose, and resistant dextrin) intake on immune function and intestinal microbiota structure in perioperative patients with colorectal cancer (CRC). METHODS: A randomized, double-blind, no-treatment parallel control clinical trial involving 140 perioperative patients (90 men and 50 women, aged 40-75 y) with CRC was performed. Patients were randomly divided into two groups: an intervention group (prebiotic group, n = 70) that received prebiotic supplementation of 30 g/d for 7 d, and a control group (non-prebiotic group, n = 70) that received no prebiotic supplementation. The nutritional and immunologic indices were evaluated for both groups before and after operation and analyzed against baseline values. Moreover, fecal samples were collected from 40 patients randomly chosen from the two groups to study intestinal microbiota, which was analyzed by sequencing the V3-V4 region of 16S ribosomal DNA using the Illumina (San Diego, CA) MiSeq (PE 2 × 300 bp) platform. RESULTS: Oral intake of prebiotics produced significant effects on immunologic indices in both the preoperative and postoperative periods, but the patterns of effects were different. In the preoperative period, prebiotics increased serum levels of immunoglobulin G (IgG; P = 0.02), IgM (P = 0.00), and transferrin (P = 0.027; all P < 0.05). In the postoperative period, enhanced levels of IgG (P = 0.003), IgA (P = 0.007), suppressor/cytotoxic T cells (CD3+CD8+; P = 0.043), and total B lymphocytes (CD19+; P = 0.012) were identified in the prebiotic group (all P < 0.05). The differences in the intestinal microbiota at the phylum level were not statistically significant between the intervention and control groups (P > 0.05). At the genus level, prebiotics increased the abundance of Bifidobacterium (P = 0.017) and Enterococcus (P = 0.02; both P < 0.05) but decreased the abundance of Bacteroides (P = 0.04) in the preoperative period (all P < 0.05). In the postoperative period, the abundance of Bacteroides (P = 0.04) was decreased, but the abundance of Enterococcus (P = 0.00), Bacillus (P = 0.01), Lactococcus (P = 0.00), and Streptococcus (P = 0.037) increased in the non-prebiotic group (all P < 0.05); however, no significant change was identified in the abundance of Enterococcus (P = 0.56), Lactococcus (P = 0.07), and Streptococcus (P = 0.56) as a result of prebiotic intervention in this period (all P > 0.05). The abundance of Escherichia-Shigella was increased after prebiotic intake in the postoperative period (P = 0.014, P < 0.05). There was a notable trend of decline in the abundance of intestinal microbiota from preoperative to postoperative in the non-prebiotic group. CONCLUSIONS: Prebiotic intake is recommended to improve serum immunologic indicators in patients with CRC 7 d before operation. Prebiotics improved the abundance of four commensal microbiota containing opportunistic pathogens in patients with CRC. Surgical stress decreased the abundance of most intestinal microbiota in the intestinal tract but increased the abundance of some opportunistic pathogens and commensal microbiota. Bacteroides is a relevant bacterial species for further research on the mechanism of prebiotics.
Experiment 1
Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/22
Curated date: 2022/09/03
Curator: Mary Bearkland
Revision editor(s): WikiWorks, LGeistlinger, Claregrieve1, Mary Bearkland, Peace Sandy
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Nutraceutical , Colorectal cancer Dietary Supplement,Food Supplementation,Nutritional supplement,Nutraceutical,nutraceutical,cancer of colorectum,cancer of large bowel,cancer of large intestine,cancer of the large bowel,colon cancer,colorectal cancer,colorectum cancer,CRC,large intestine cancer,malignant colorectal neoplasm,malignant colorectal tumor,malignant colorectum neoplasm,malignant large bowel neoplasm,malignant large bowel tumor,malignant large intestine neoplasm,malignant large intestine tumor,malignant neoplasm of colorectum,malignant neoplasm of large bowel,malignant neoplasm of large intestine,malignant neoplasm of the large bowel,malignant neoplasm of the large intestine,malignant tumor of large bowel,malignant tumor of large intestine,malignant tumor of the large bowel,malignant tumor of the large intestine,Colorectal cancer
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- colorectal cancer patients who didn't take prebiotics (preoperative fecal sample)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- colorectal cancer patients who took prebiotics (preoperative fecal sample)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with radiologic and pathologic diagnosis of CRC (preoperatively). Patients in the intervention group (prebiotic group) received a daily oral dose of 30 g prebiotic supplement (Hangzhou Niuqu Biotech Co., Hainengbo, China) containing fructooligosaccharide (25%), xylooligosaccharide (25%), polydextrose (25%), and resistant dextrin (25%) for 7 d from hospitalization to the day before the operation.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 20
- Group 1 sample size Number of subjects in the case (exposed) group
- 18
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- no treatment with antibiotics within 6 mo before surgery
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Mann-Whitney (Wilcoxon)
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
Signature 1
Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/22
Source: Table 4; Table 3
Description: Differential microbial abundance between patients who took prebiotics and patients who did not
Abundance in Group 1: decreased abundance in colorectal cancer patients who took prebiotics (preoperative fecal sample)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacteroides | ||
| Enterococcus |
Revision editor(s): Mary Bearkland, Claregrieve1
Signature 2
Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/22
Source: Table 4; Table 3
Description: Differential microbial abundance between patients who took prebiotics and patients who did not
Abundance in Group 1: increased abundance in colorectal cancer patients who took prebiotics (preoperative fecal sample)
| NCBI | Quality Control | Links |
|---|---|---|
| Bifidobacterium |
Revision editor(s): Mary Bearkland, Claregrieve1
Experiment 2
Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/22
Curated date: 2022/09/03
Curator: Mary Bearkland
Revision editor(s): Mary Bearkland, Claregrieve1, WikiWorks
Differences from previous experiment shown
Subjects
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Nutraceutical , Colorectal cancer Dietary Supplement,Food Supplementation,Nutritional supplement,Nutraceutical,nutraceutical,cancer of colorectum,cancer of large bowel,cancer of large intestine,cancer of the large bowel,colon cancer,colorectal cancer,colorectum cancer,CRC,large intestine cancer,malignant colorectal neoplasm,malignant colorectal tumor,malignant colorectum neoplasm,malignant large bowel neoplasm,malignant large bowel tumor,malignant large intestine neoplasm,malignant large intestine tumor,malignant neoplasm of colorectum,malignant neoplasm of large bowel,malignant neoplasm of large intestine,malignant neoplasm of the large bowel,malignant neoplasm of the large intestine,malignant tumor of large bowel,malignant tumor of large intestine,malignant tumor of the large bowel,malignant tumor of the large intestine,Colorectal cancer
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- colorectal cancer patients non-prebiotic (preoperative)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- colorectal cancer patients non-prebiotic (postoperative)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with radiologic and pathologic diagnosis of CRC who underwent radical resection (post-operative samples) and did not take prebiotics pre-surgery.
- Group 1 sample size Number of subjects in the case (exposed) group
- 20
Lab analysis
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- Not specified
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
Signature 1
Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/22
Source: Table 5
Description: Differential microbial abundance between the pre- and postoperative timepoints in patients who did not take prebiotics
Abundance in Group 1: decreased abundance in colorectal cancer patients non-prebiotic (postoperative)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacteroides |
Revision editor(s): Mary Bearkland, Claregrieve1
Signature 2
Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/22
Source: Table 5
Description: Differential microbial abundance between the pre- and postoperative timepoints in patients who did not take prebiotics
Abundance in Group 1: increased abundance in colorectal cancer patients non-prebiotic (postoperative)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacillus | ||
| Enterococcus | ||
| Lactococcus | ||
| Streptococcus |
Revision editor(s): Mary Bearkland, Claregrieve1
Experiment 3
Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/22
Curated date: 2022/09/03
Curator: Mary Bearkland
Revision editor(s): Mary Bearkland, Claregrieve1, WikiWorks
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- colorectal cancer patients who took prebiotics (preoperative fecal sample)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- colorectal cancer patients who took prebiotics (postoperative fecal sample)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with radiologic and pathologic diagnosis of CRC who underwent radical resection (post-operative samples) and took prebiotics pre-surgery.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 18
- Group 1 sample size Number of subjects in the case (exposed) group
- 18
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
Signature 1
Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/22
Source: Table 5; Figure 3
Description: Differential microbial abundance between the pre- and postoperative timepoints in patients who took prebiotics
Abundance in Group 1: increased abundance in colorectal cancer patients who took prebiotics (postoperative fecal sample)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacillus | ||
| Bifidobacterium | ||
| Enterococcus | ||
| Escherichia/Shigella sp. |
Revision editor(s): Mary Bearkland, Claregrieve1
Signature 2
Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/22
Source: Table 5; Figure 3
Description: Differential microbial abundance between the pre- and postoperative timepoints in patients who took prebiotics
Abundance in Group 1: decreased abundance in colorectal cancer patients who took prebiotics (postoperative fecal sample)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacteroides |
Revision editor(s): Mary Bearkland, Claregrieve1
Retrieved from "https://bugsigdb.org/w/index.php?title=Study_692&oldid=101414"
Hidden category:
